NZ595431A - 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 - Google Patents
4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2Info
- Publication number
- NZ595431A NZ595431A NZ595431A NZ59543110A NZ595431A NZ 595431 A NZ595431 A NZ 595431A NZ 595431 A NZ595431 A NZ 595431A NZ 59543110 A NZ59543110 A NZ 59543110A NZ 595431 A NZ595431 A NZ 595431A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ccr2
- azetidin
- trifluoromethyl
- cyclohexyl
- compounds
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000002975 chemoattractant Substances 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- RHUGJMIZMHMWOL-UHFFFAOYSA-N methyl n-[5-[4-[3-[[2-[[3-(trifluoromethyl)benzoyl]amino]acetyl]amino]azetidin-1-yl]cyclohexyl]-1,3-thiazol-2-yl]carbamate Chemical compound S1C(NC(=O)OC)=NC=C1C1CCC(N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 RHUGJMIZMHMWOL-UHFFFAOYSA-N 0.000 abstract 1
- CXQAXZFTIBOKGV-UHFFFAOYSA-N n-[2-[[1-[4-(3-amino-5-imino-4h-1,2-oxazol-4-yl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC(=O)NC2CN(C2)C2CCC(CC2)C2C(ONC2=N)=N)=C1 CXQAXZFTIBOKGV-UHFFFAOYSA-N 0.000 abstract 1
- KJPDQGXTTPNKFG-UHFFFAOYSA-N n-[2-[[1-[4-fluoro-4-(6-methoxypyridin-3-yl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(OC)=CC=C1C1(F)CCC(N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 KJPDQGXTTPNKFG-UHFFFAOYSA-N 0.000 abstract 1
- YGALFKXWBYAMQL-UHFFFAOYSA-N n-[2-oxo-2-[[1-[4-(5-pyrrolidin-1-yl-1,2,4-oxadiazol-3-yl)cyclohexyl]azetidin-3-yl]amino]ethyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC(=O)NC2CN(C2)C2CCC(CC2)C=2N=C(ON=2)N2CCCC2)=C1 YGALFKXWBYAMQL-UHFFFAOYSA-N 0.000 abstract 1
- JCCGSOVTBIJRGP-UHFFFAOYSA-N n-piperidin-1-ylprop-2-enamide Chemical class C=CC(=O)NN1CCCCC1 JCCGSOVTBIJRGP-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16987609P | 2009-04-16 | 2009-04-16 | |
| PCT/US2010/031212 WO2010121011A1 (en) | 2009-04-16 | 2010-04-15 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595431A true NZ595431A (en) | 2013-12-20 |
Family
ID=42154522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595431A NZ595431A (en) | 2009-04-16 | 2010-04-15 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8269015B2 (enExample) |
| EP (1) | EP2419417B1 (enExample) |
| JP (1) | JP5685580B2 (enExample) |
| KR (1) | KR20120061060A (enExample) |
| CN (1) | CN102459225B (enExample) |
| AR (1) | AR076310A1 (enExample) |
| AU (1) | AU2010236393B2 (enExample) |
| BR (1) | BRPI1016207A2 (enExample) |
| CA (1) | CA2758918A1 (enExample) |
| ES (1) | ES2539161T3 (enExample) |
| MX (1) | MX2011010919A (enExample) |
| NZ (1) | NZ595431A (enExample) |
| TW (1) | TW201105649A (enExample) |
| WO (1) | WO2010121011A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2745969C (en) * | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| ES2528625T3 (es) * | 2009-04-17 | 2015-02-11 | Janssen Pharmaceutica Nv | Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2 |
| CA2758929A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 |
| TW201211027A (en) * | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| WO2011159854A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of ccr2 |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| RU2726206C2 (ru) | 2015-05-21 | 2020-07-09 | Кемосентрикс, Инк. | Модуляторы ccr2 |
| EP3687525B1 (en) | 2017-09-25 | 2025-10-29 | ChemoCentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037354A (en) | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| CA2378499A1 (en) | 1999-08-04 | 2001-02-15 | Teijin Limited | Cyclic amine ccr3 antagonists |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| AR035773A1 (es) * | 2000-12-20 | 2004-07-14 | Bristol Myers Squibb Pharma Co | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina |
| UA87449C2 (ru) * | 2002-11-27 | 2009-07-27 | Инсайт Корпорейшн | Производные 3-аминопиролидина как модуляторы рецепторов хемокина |
| WO2004050024A2 (en) * | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| KR20070063562A (ko) | 2004-09-28 | 2007-06-19 | 얀센 파마슈티카 엔.브이. | 치환 디피페리딘 ｃｃｒ２ 길항제 |
| PA8653301A1 (es) | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| AU2008335135A1 (en) * | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| CA2745969C (en) * | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| CA2758929A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 |
| ES2528625T3 (es) | 2009-04-17 | 2015-02-11 | Janssen Pharmaceutica Nv | Antagonistas de 4-azetidinil-1-fenil-ciclohexano de CCR2 |
-
2010
- 2010-04-15 NZ NZ595431A patent/NZ595431A/en not_active IP Right Cessation
- 2010-04-15 JP JP2012506216A patent/JP5685580B2/ja not_active Expired - Fee Related
- 2010-04-15 WO PCT/US2010/031212 patent/WO2010121011A1/en not_active Ceased
- 2010-04-15 EP EP10714148.3A patent/EP2419417B1/en active Active
- 2010-04-15 AU AU2010236393A patent/AU2010236393B2/en not_active Ceased
- 2010-04-15 KR KR1020117026815A patent/KR20120061060A/ko not_active Withdrawn
- 2010-04-15 TW TW099111730A patent/TW201105649A/zh unknown
- 2010-04-15 AR ARP100101263A patent/AR076310A1/es unknown
- 2010-04-15 CA CA2758918A patent/CA2758918A1/en not_active Abandoned
- 2010-04-15 MX MX2011010919A patent/MX2011010919A/es active IP Right Grant
- 2010-04-15 BR BRPI1016207A patent/BRPI1016207A2/pt not_active Application Discontinuation
- 2010-04-15 US US12/760,832 patent/US8269015B2/en not_active Expired - Fee Related
- 2010-04-15 CN CN201080027215.2A patent/CN102459225B/zh not_active Expired - Fee Related
- 2010-04-15 ES ES10714148.3T patent/ES2539161T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8269015B2 (en) | 2012-09-18 |
| JP2012524107A (ja) | 2012-10-11 |
| JP5685580B2 (ja) | 2015-03-18 |
| TW201105649A (en) | 2011-02-16 |
| ES2539161T3 (es) | 2015-06-26 |
| CN102459225A (zh) | 2012-05-16 |
| MX2011010919A (es) | 2011-11-02 |
| WO2010121011A1 (en) | 2010-10-21 |
| CA2758918A1 (en) | 2010-10-21 |
| AU2010236393A1 (en) | 2011-11-03 |
| EP2419417B1 (en) | 2015-03-25 |
| KR20120061060A (ko) | 2012-06-12 |
| US20100267688A1 (en) | 2010-10-21 |
| CN102459225B (zh) | 2014-08-20 |
| EP2419417A1 (en) | 2012-02-22 |
| AR076310A1 (es) | 2011-06-01 |
| AU2010236393B2 (en) | 2014-11-13 |
| BRPI1016207A2 (pt) | 2016-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11697636B2 (en) | Substituted benzamides | |
| CN101321525B (zh) | 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物 | |
| NZ595433A (en) | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 | |
| US8853218B2 (en) | Compounds | |
| JP2012510515A5 (enExample) | ||
| PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
| NZ586301A (en) | Benzothiazole and benzoxazole derivatives and methods of use | |
| CA2719000A1 (en) | Piperidine derivatives as inhibitors of stearoyl-coa desaturase | |
| RU2012121684A (ru) | Производные оксазолина для лечения заболеваний цнс | |
| NZ617334A (en) | Cyclopropyl amine derivatives | |
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2007519754A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| WO2008139235A8 (en) | Novel piperazine salts as d3/d2 antagonists | |
| JP2008538749A5 (enExample) | ||
| JP2006510609A5 (enExample) | ||
| JP2010506918A5 (enExample) | ||
| NZ595432A (en) | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| PE20110928A1 (es) | Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 | |
| JP2012512252A5 (enExample) | ||
| RU2005136535A (ru) | Новые азетидиновые соединения | |
| NZ595797A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| Walker et al. | Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase | |
| TH58983A (th) | การใช้ nk-1 รีเซพเตอร์แอนตาโกนิสต์สำหรับการผลิตเวชภัณฑ์เพื่อการรักษา และ/หรือการป้องกันการบาดเจ็บทางสมอง, กระดูกสันหลัง หรือประสาท |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2017 BY CPA GLOBAL Effective date: 20140602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2020 BY CPA GLOBAL Effective date: 20140906 |
|
| LAPS | Patent lapsed |